Here's a classic biotech puzzle: what happens when a company reports good clinical trial data and its stock goes down anyway? That's exactly what happened with Maze Therapeutics Inc. (MAZE) on Wednesday.

The company announced topline results from its Phase 2 HORIZON trial for MZE829, an oral treatment for APOL1-mediated kidney disease (AMKD). For those not up on their kidney disease terminology, AMKD is caused by genetic variants in the APOL1 gene. The results looked pretty solid - patients treated with MZE829 showed a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR), which is a key measure of kidney function. Half of the patients achieved reductions of over 30%.

Let's pause for a quick science lesson: uACR measures albumin (a blood protein) and creatinine (a waste product) in urine. Healthy kidneys keep albumin out of urine, so a normal result is less than 30 mg/g. Higher numbers mean kidney trouble.

Now here's where it gets interesting. Patients with a specific condition called focal segmental glomerulosclerosis (FSGS) - that's a rare disease where scarring develops in kidney filters - saw an impressive 61.8% mean reduction in uACR. And in patients with AMKD but without diabetes, the mean reduction was 48.6%.

The trial involved 15 patients for safety analysis, with 12 evaluated for efficacy. The drug was well-tolerated across all doses tested. Based on these results, Maze plans to advance MZE829 to a pivotal program while continuing to enroll patients in the HORIZON study.

So why did the stock drop 31.17% to $33.72? That's the million-dollar question (or in this case, the multi-million dollar question). Sometimes the market reacts to what it expected versus what it got, or maybe there were details in the data that concerned some investors. What we do know is that analysts aren't running for the hills.

The stock carries a Buy rating with an average price target of $56.33. Recent analyst moves include HC Wainwright raising its target to $110 on March 25, Truist Securities initiating with a Buy and $68 target on March 18, Wedbush raising its target to $58 on March 16, and Mizuho initiating with an Outperform rating and $97 target on March 10.

Financially, Maze reported a 2025 cash balance of $360 million, which should fund operations into 2028. That gives the company plenty of runway to continue developing MZE829 without immediate fundraising pressure.

So we're left with a biotech story that has all the elements: promising clinical data, analyst support, solid cash position, and a stock that decides to move in the opposite direction of what you might expect. Welcome to the wonderful world of drug development investing.